Health ❯Healthcare ❯Pharmaceuticals ❯Drug Approval

FDA

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC

The decision rests on phase 3 data showing a 68% lower risk of recurrence or death versus placebo.

FDA Approves Zoryve 0.05% Cream for Children Ages 2–5 With Mild to Moderate Atopic Dermatitis

FDA Approves Lilly’s Inluriyo for ESR1‑Mutated Advanced Breast Cancer

FDA Clears Shot Version of Keytruda as EU Panel Backs Approval